Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study

Blood

Volumn 108, Issue 5, 2006, Pages 1562-1568

  Frère, Corinne ^c   Tregouet, David Alexandre ^c   Morange, Pierre Emmanuel ^c   Saut, Noémie ^c   Kouassi, Dinar ^c   Juhan Vague, Irène ^c   Tiret, Laurence ^c   Alessi, Marie Christine ^a,b  

^a INSERM   (France)

^b TIMONE HOSPITAL   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; NUCLEOTIDE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; FIBRINOLYSIS; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MALE; NUCLEIC ACID ANALYSIS; POPULATION GENETICS; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS;

EID: 33748132990     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-01-008094     Document Type: Article

References (41)

1. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 1995;34:5811-5816.
2. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem. 1991;266:21833-21838.
3. Hendriks D, Scharpe S, van Sande M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem. 1989;27:277-285.
4. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603-16608.
5. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem. 1998;273:2127-2135.
6. Kokame K, Zheng X, Sadler JE. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem. 1998;273:12135-12139.
7. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176-27181.
8. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem. 1997;272:14477-14482.
9. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855-2859.
10. Silveira A, Schatteman K, Goossens F, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000;84:364-368.
11. Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:660-665.
12. Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost. 2000;83:902-905.
13. Stromqvist M, Schatteman K, Leurs J, et al. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost. 2001;85:12-17.
14. Guo X, Morioka A, Kaneko Y, et al. Arginine carboxypeptidase (CPR) in human plasma determined with sandwich ELISA. Microbiol Immunol. 1999;43:691-698.
15. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001;97:2053-2058.
16. Franco RF, Fagundes MG, Meijers JC, et al. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica. 2001;86:510-517.
17. Tregouet DA, Aubert H, Henry M, et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet. 2001;109:191-197.
18. Boffa MB, Reid TS, Joo E, Nesheim ME, Koschinsky ML. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry. 1999;38:6547-6558.
19. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem. 2002;277:1021-1030.
20. Zhao L, Morser J, Bajzar L, Nesheim M, Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost. 1998;80:949-955.
21. Brouwers GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood. 2001;98:1992-1993.
22. Guimaraes AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol. 2004;124:659-665.
23. Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol. 2003;23:1122-1127.
24. Morange PE, Tregouet DA, Frere C, et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost. 2005;3:1503-1510.
25. Frere C, Morange PE, Saut N, et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost. 2005;94:373-379.
26. Crawford DC, Carlson CS, Rieder MJ, et al. Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am J Hum Genet. 2004;74:610-622.
27. Shifman S, Kuypers J, Kokoris M, Yakir B, Darvasi A. Linkage disequilibrium patterns of the human genome across populations. Hum Mol Genet. 2003;12:771-776.
28. Lonjou C, Zhang W, Collins A, et al. Linkage disequilibrium in human populations. Proc Natl Acad Sci U S A. 2003;100:6069-6074.
29. Armour JA, Anttinen T, May CA, et al. Minisatellite diversity supports a recent African origin for modern humans. Nat Genet. 1996;13:154-160.
30. Cox R, Bouzekri N, Martin S, et al. Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides. Hum Mol Genet. 2002;11:2969-2977.
31. McKenzie CA, Abecassis GR, Keavney B, et al. Trans-ethnic fine mapping of a quantitative trait locus for circulating angiotensin I-converting enzyme (ACE). Hum Mol Genet. 2001;10:1077-1084.
32. Cost H, Grimaux M, Grosley M, Woodhams B. A new antigen assay independent of polymorphisms 325Thr/Ile and 147 Ala/Thr [abstract]. Pathophysiol Haemost Thromb. 2004;33:64.
33. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
34. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet. 2004;68:165-177.
35. Nei M. Molecular Evolutionary Genetics. New York, NY: Columbia University Press; 1987.
36. Clement M, Posada D, Crandall KA. TCS: a computer program to estimate gene genealogies. Mol Ecol. 2000;9:1657-1659.
37. Sawyer SL, Mukherjee N, Pakstis AJ, et al. Linkage disequilibrium patterns vary substantially among populations. Eur J Hum Genet. 2005;13:677-686.
38. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
39. Reich DE, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. Nature. 2001;411:199-204.
40. Maret D, Brien DF, Franco RF, Nesheim ME, Koschinsky ML, Boffa MB. Polymorphisms in the 3-untranslated region of the TAFI mRNA modulate TAFI gene expression through control of mRNA stability [abstract]. J Thromb Haemost. 2003;1(suppl 1):OC61.
41. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95:221-227.